Safety-first, oversight-driven regenerative protocol designed specifically for the paediatric population and implemented hand-in-hand with participating clinics worldwide.
The protocol is designed around the needs of paediatric patients, with age-adapted preparation, observation, and therapy support at every stage.
Participating clinics maintain response protocols, emergency pathways, and continuous patient monitoring throughout every stage of treatment.
Cell biologics are handled according to applicable local rules, clinic requirements, and medical governance standards at each participating location.
The Neorgana Paediatric Program is led by a medical director with more than a decade in paediatric neuroregeneration, treating children with complex neurological conditions every week. The protocol was built around Dezawa MuseCells® from the ground up, and the team behind it spans neuroregeneration, emergency medicine and anaesthesiology.

More than a decade of clinical experience specialising in paediatric neuroregeneration. Medical Director of Neorgana Regenerative and one of the leading specialists worldwide in the clinical application of Dezawa MuseCells® for paediatric patients, treating children with complex neurological conditions each week. The Neorgana protocol was designed around this specific cell type from the ground up.

Dr. Salazar contributes expertise in emergency medicine, advanced cardiopulmonary resuscitation and clinical preparedness for complex paediatric cases.

Dr. Abud earned her medical degree from Universidad Anáhuac Mayab and completed her undergraduate medical internship at the University Hospital of Santiago de Compostela in Spain. She later completed her anaesthesiology specialty training at Hospital General Dr. Agustín O'Horán in Mérida, Yucatán. Professional licence: 12138042.
"We had researched every option available for two years. The level of documentation, the chain-of-custody verification, and the way the team communicated with us throughout — nothing we had encountered matched it. Three months after treatment, our son began making progress we had not seen in years."
The team explained every step before it happened. As a parent you need to understand what is going into your child's body and why. They never made us feel like we were asking too many questions.
What gave us confidence was seeing the actual documentation. Every transfer was logged. We knew exactly where the cells had come from and how they had been handled before reaching our daughter.
Our child's neurologist at home was sceptical. After seeing the protocol documentation we had brought back, she told us it was the most structured regenerative programme she had reviewed.
Every child’s course is different. These are individual family experiences and are not a promise of any particular outcome; candidacy and all treatment decisions are made by qualified medical professionals.
Our protocol combines regenerative cell administration, via the intranasal route, the intravenous route, or both, with supportive neurological preparation and cellular integration therapies. The delivery method and sequence may vary based on each child's needs, clinical review, and participating clinic protocols. Designed exclusively with Dezawa MuseCells® technology.
Paediatric intake and a thorough functional review, mapping each child's precise neurological profile to guide the treatment plan.
Supportive therapies chosen for that profile and the child's readiness, creating an optimal environment for cellular integration.
Preparation continues until the child is ready, so administration begins under the best possible conditions.
Dezawa MuseCells® are administered intranasally, intravenously, or both. The route is a clinical decision made for each child from their profile and treatment plan.
When it is your child receiving treatment, every handoff matters. Neorgana documents and verifies each patient's Dezawa MuseCells® at every stage of the journey, from the originating lab to the moment of administration. Nothing is left to assumption.
Regeneration is more than cell administration. Supportive therapies help prepare the nervous system, reinforce neurological communication, and create a more organised environment for integration.

Neorgana's Paediatric NeuroRegeneration Program combines rigorous medical oversight with extensive expertise in the biology of authentic Dezawa MuseCells®. Rather than simply administering regenerative cells, we engineer the optimal biological environment and treatment strategy to support their natural homing, tissue integration, and regenerative function. Our protocols are designed around this specific technology. For your child, that means a treatment built for their biology, not adapted from something else.
Cells migrate and home to damaged tissue, targeting where regeneration is needed most.
Actively release molecules that support tissue repair and neuroplasticity.
Differentiate into neural-supportive cell types and integrate into damaged tissue.
Everything in this programme rests on one thing: the cell it begins with. The protocol, the oversight and the documentation are only ever as good as that.
Authentic Dezawa MuseCells® are a naturally occurring cell type. They are identified by a specific surface marker and isolated through a defined selection process developed in Dr. Mari Dezawa’s laboratory at Tohoku University. Their pluripotency is intrinsic to the cell, and the genome stays intact.
One organisation stands behind that cell. MuseCell Innovations® is the global IP owner: it holds the intellectual property covering the methods used to isolate and enrich authentic Muse cells, developed in collaboration with Tohoku University, and it authorises distribution only through approved partners. Neorgana is one of them.
The word “Muse” on its own carries no guarantee. Products have entered the market under that name without demonstrated provenance from that platform, and a family reading a clinic’s website has no way to sort one from the other. The studies parents are handed, and the safety record they are shown, describe the authentic cell type, and only that.
There is a better question to ask any clinic than whether they use Muse cells. Ask them to show you where the cells came from, and to prove it for your child.
It is public, and it is worth your time before you choose any clinic, including ours.
Read the white paperNeorgana operates clinics in México, with Dubai opening in December 2026 and the United States in 2027.



For medically complex cases requiring hospital-level clinical oversight
When a child is involved, every detail matters. The Neorgana Paediatric Program is built around preparation, verification, safety monitoring, and a structured regenerative protocol.
From the first intake to final administration, the process is designed to prioritise paediatric safety, clear documentation, and careful coordination between the lab, clinic, medical team, and family.

An investigator-initiated clinical trial examining the safety profile of Muse cells in neonates with hypoxic-ischaemic encephalopathy alongside therapeutic cooling. Nine patients received intravenous administration with no significant adverse events recorded. All patients survived; two-thirds achieved normal developmental scores across cognitive domains at follow-up.
Read the researchStart a WhatsApp conversation to request a complimentary consultation with a member of the Neorgana team. This informational call helps your family learn more about the programme and understand the next available steps.
We have prepared the first message for you. You can review or edit it before sending.
Continue to WhatsApp Opens a private chat with a pre-filled messageChoose the topic that best matches your question. WhatsApp will open with the right context already written for our team.
Find out what information the team needs to begin.
Explore our clinics and where we are opening next.
Understand the process before requesting a consultation.
Leave your details for our Dubai clinic, opening December 2026.
All treatment decisions are made by qualified medical professionals. A clinical review is required for candidacy. We respond to all enquiries within 2 business days.
We respect your privacy.